An Interactive Learning ExperienceThis course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com
How does your management of patients with migraine compare to the experts? By participating in this six-part educational initiative, which incorporates a comprehensive roundtable faculty discussion, augmented reality, and a patient narrative, you will be able to incorporate key information into your clinical practice immediately.
All migraine patients need acute migraine treatment. And yet, approximately 50% of patients remain undertreated primarily owing to the adverse effect profiles of older, non-targeted treatments, or because of contraindications to triptans. New targeted drug classes are now available for acute migraine treatment, including oral small-molecule CGRP antagonists (gepants) and selective serotonin antagonists (ditans). These new migraine-specific acute treatment options provide an effective means of improving adherence and reducing migraine-related disability and socioeconomic burden.
Migraine affects 1 in 7 people worldwide and is the second leading cause of all global disability. Primary care practitioners are often the first contact for patients with migraine, yet it can be challenging to distinguish migraine from other headache disorders and remain current on best practices for management. Tune in to this session, developed by the American Headache Society as part of the First Contact – Headache in Primary Care initiative to learn strategies for accurate and timely identification of migraine and review updates to management.
The entire field of migraine is witnessing a profound and unprecedented transformation with new therapeutic options now available to address serious unmet medical needs and patient burden. The new options range from monoclonal antibodies (mAbs) targeting the CGRP ligand or receptor for migraine prevention, to a selective serotonin agonist, to oral CGRP-targeting agents (gepants) now approved for both preventive and acute treatment. These new advances are creating a vitality and excitement in the field not seen since the advent of triptans more than 2 decades ago.